Vumon Uses, Dosage, Side Effects and more
Vumon is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Vumon inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Vumon acts primarily in the G2 and S phases of the cycle.
Vumon is a phase-specific cytotoxic drug, acting in the late S or early G 2 phase of the cell cycle. Vumon prevents cell mitosis by causing single and double stranded DNA breaks as well as cross linking between protein and DNA.
| Attribute | Details |
|---|---|
| Trade Name | Vumon |
| Availability | Discontinued |
| Generic | Teniposide |
| Teniposide Other Names | Epidophyllotoxin, Teniposid, Téniposide, Teniposide, Teniposido, Teniposidum |
| Related Drugs | prednisone, methotrexate, rituximab, Rituxan, doxorubicin, cyclophosphamide, Deltasone, imatinib, Gleevec, vincristine |
| Weight | 10mg/ml, |
| Type | Intravenous solution |
| Formula | C32H32O13S |
| Weight | Average: 656.654 Monoisotopic: 656.1563618 |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | Bristol-Myers Squibb Farmacêutica Portuguesa, SA |
| Available Country | Canada, United States, Portugal |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Vumon is a cytotoxic drug used as an adjunct for chemotherapy induction in the treatment of refractory childhood acute lymphoblastic leukemia.
Vumon is used for the treatment of refractory acute lymphoblastic leukaemia
Vumon is also used to associated treatment for these conditions: Acute Lymphoblastic Leukaemia Recurrent, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Atopic dermatitis
How Vumon works
The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA. Vumon binds to and inhibits DNA topoisomerase II. The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which are a reflection of the stabilization of a topoisomerase II-DNA intermediate.
Food Interaction
- Exercise caution with grapefruit products. Vumon is a CYP3A4 substrate, and grapefruit inhibits CYP3A4 metabolism, coadministration may increase the serum concentrations of teniposide.
- Exercise caution with St. John's Wort. Vumon is a CYP3A4 substrate, and St. John's Wort induces CYP3A4 metabolism, coadministration may reduce the serum concentrations of teniposide.
Disease Interaction
Major: infections, myelosuppressionModerate: hepatic dysfunction, renal dysfunction
Half Life
5 hours
Clearance
- 10.3 mL/min/m2
Elimination Route
From 4% to 12% of a dose is excreted in urine as parent drug. Fecal excretion of radioactivity within 72 hours after dosing accounted for 0% to 10% of the dose.
